RORC and chronic obstructive pulmonary disease: PCCR-2, has shown a favorable safety profile in all Phase 1 enabling 4-week repeat dose administration studies in both rats and dogs, and has been successfully progressed to Phase 1 human Clinical Trial evaluation in USA as a potent RORγ inhibitor for COPD via-inhalation route (Clinical trial IND 144,906).